U.S. Tobacco Stock News

NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

Stronger 2025 Results, Higher Dividend and Buyback Might Change The Case For Investing In LeMaitre Vascular (LMAT)

LeMaitre Vascular, Inc. recently reported fourth-quarter 2025 sales of US$64.45 million and net income of US$15.58 million, alongside full-year 2025 sales of US$249.6 million and net income of US$57.73 million, and announced a higher quarterly dividend of US$0.25 per share plus a share repurchase program of up to US$100 million through February 18, 2027. In addition, the company issued 2026 guidance that points to higher sales and earnings and plans to highlight its outlook at the Leerink...
NYSE:YALA
NYSE:YALAInteractive Media and Services

Assessing Yalla Group (YALA) Valuation After New US$150 Million Buyback And Q1 2026 Revenue Guidance

Why Yalla Group (YALA) is back on investors’ radar Yalla Group (YALA) has drawn fresh attention after its board approved a new share repurchase program of up to US$150 million, alongside first quarter 2026 revenue guidance that factors in the timing of Ramadan. See our latest analysis for Yalla Group. Those moves come after a period where the 1 year total shareholder return of 76.9% contrasts with a more muted 0.7% year to date share price return at US$7.11, suggesting recent momentum has...
NYSE:MTD
NYSE:MTDLife Sciences

Why Mettler-Toledo (MTD) Is Down 5.8% After Tariff-Driven Margin Squeeze And Cautious 2025 Outlook

In Q2 2025, Mettler-Toledo International reported marginal revenue growth but weaker gross and operating margins as higher tariffs and macroeconomic pressures weighed on profitability, and management issued cautious full-year 2025 guidance. Even as near-term earnings face pressure, the company is emphasizing bioprocessing and manufacturing onshoring as areas it believes could reshape its longer-term business mix. We’ll now examine how the tariff-driven margin squeeze highlighted in the...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences EHR Outreach Lifts CRC Screening And Fuels Investor Interest

Exact Sciences, Amalgam Rx and Privia Health report materially higher colorectal cancer screening rates using EHR-enabled outreach and at home noninvasive tests. The coordinated program is described as scalable and has surpassed national screening benchmarks during Colorectal Cancer Awareness Month. The initiative focuses on closing screening gaps by embedding screening prompts and workflows directly into clinical systems and patient communications. For investors watching NasdaqCM:EXAS,...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement

Why Nurix Therapeutics (NRIX) moved after its latest capital move Nurix Therapeutics (NRIX) recently expanded its equity distribution agreement, giving it room to sell up to $413.65 million of common stock through Piper Sandler. This step directly affects its capital-raising flexibility and potential dilution. See our latest analysis for Nurix Therapeutics. The capital plan arrives after a tougher few months for the share price, with a 30 day share price return showing an 8% decline and a 90...
NasdaqCM:AXGN
NasdaqCM:AXGNMedical Equipment

Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors?

In February 2026, Axogen, Inc. reported past full-year 2025 results, with sales rising to US$225.21 million from US$187.34 million, while net loss widened to US$15.70 million and basic loss per share from continuing operations increased to US$0.34 from US$0.23. On the same date, Axogen issued new 2026 guidance calling for at least 18% revenue growth to about US$265.70 million and gross margins between 74% and 76%, highlighting management’s confidence in the underlying demand for its nerve...
NYSE:INSP
NYSE:INSPMedical Equipment

A Look At Inspire Medical Systems (INSP) Valuation After Strong Earnings Beat And Guidance Raise

Why Inspire Medical Systems is back on investors' radar Inspire Medical Systems (INSP) recently reported a strong quarter, with revenue above expectations, 12.2% year over year growth, and a full year guidance raise that ranked highest among its sector peers. See our latest analysis for Inspire Medical Systems. Despite the recent earnings beat and guidance raise, the share price has been under pressure, with a 90 day share price return of 56.0% and a 1 year total shareholder return of 65.5%...
NYSE:VTOL
NYSE:VTOLEnergy Services

Will Solid Q4 Results, Dividend, And 2026 Guidance Change Bristow Group's (VTOL) Narrative

On February 25, 2026, Bristow Group Inc. reported fourth-quarter 2025 sales of US$377.26 million and net income of US$18.42 million, alongside a US$0.125 quarterly dividend and affirmed 2026 revenue guidance of US$1.58 billion to US$1.69 billion. The combination of stronger full-year 2025 profitability, reiterated revenue expectations for 2026, and continued cash returns via dividends underscores management’s confidence in Bristow’s operating outlook. With 2026 revenue guidance now on the...
NasdaqGS:PLXS
NasdaqGS:PLXSElectronic

Assessing Plexus (PLXS) Valuation After A Strong 1 Year Share Price Rally

Recent share performance and what it means for Plexus (PLXS) investors Plexus (PLXS) has caught investor attention after a strong past 3 months, with a total return above 20% and a 1 year return above 50%, despite a weaker month. That mix of shorter term softness and stronger longer term gains raises a practical question for you as an investor: whether the current share price around $191.58 still lines up with the company’s fundamentals. See our latest analysis for Plexus. Recent trading has...
NYSE:VNT
NYSE:VNTElectronic

Is Vontier (VNT) Quietly Recasting Its Software Identity With TN360 ACM And New Innovation Leadership?

In late February 2026, Vontier’s Teletrac Navman unit enhanced its TN360 ACM construction asset management platform with real-time cost and revenue visibility, while the company also announced the upcoming retirement of director Christopher J. Klein at the 2026 Annual Meeting. Vontier’s appointment of Rasha Hasaneen as Chief Innovation and Growth Officer, alongside the TN360 ACM upgrades, highlights a stronger push into AI-enabled, software-driven growth. Next, we’ll examine how Vontier’s...
NYSE:EIX
NYSE:EIXElectric Utilities

How Investors May Respond To Edison International (EIX) Wildfire Risks Clouding Extended EPS Growth Targets

In late February, several analysts updated their views on Edison International, highlighting its extended 5%–7% EPS growth target through 2030 while emphasizing persistent risks from California wildfire reform, SB 254 legislation, and ongoing Eaton Fire litigation. These developments underline how Edison International’s core identity as a regulated utility for income-focused investors is increasingly shaped by wildfire liability uncertainty, regulatory decisions, and large grid-modernization...
NYSE:NGVT
NYSE:NGVTChemicals

Assessing Ingevity (NGVT) Valuation After Impairment Charge And 2026 Guidance Update

Ingevity (NGVT) shares came into focus after the company booked a long lived assets impairment charge of US$109.3 million in the fourth quarter and paired that with fresh 2026 net sales guidance. See our latest analysis for Ingevity. The impairment charge and weaker quarterly results appear to have cooled short term sentiment, with a 7 day share price return of 7.76% decline and a 30 day share price return of 9.09% decline. However, the 90 day share price return of 17.89% and 1 year total...
NYSE:RACE
NYSE:RACEAuto

Ferrari (NYSE:RACE) Valuation Check After Recent Share Price Weakness And Premium P/E Multiple

How Ferrari (NYSE:RACE) Has Been Trading Recently Ferrari (NYSE:RACE) has seen mixed share performance, with a 1 day return of about a 1% decline and a 7 day move of roughly a 4% decline, while the 1 month return sits near 4%. Over the past 3 months the stock shows about an 8% decline and the year to date return is roughly a 7% decline, with the 1 year total return around a 20% decline for investors holding through that period. See our latest analysis for Ferrari. At a share price of...
NYSE:ECG
NYSE:ECGConstruction

Strong 2025 Results and Acquisition Drive Might Change The Case For Investing In Everus Construction Group (ECG)

In late February 2026, Everus Construction Group reported past fourth-quarter 2025 sales of US$1,011.47 million and full-year sales of US$3.75 billion, with net income of US$55.28 million for the quarter and US$201.77 million for the year, alongside revenue guidance of US$4.10 billion to US$4.20 billion for 2026. A day later, management highlighted a strengthened balance sheet and active M&A pipeline, signaling an intention to use acquisitions to broaden Everus Construction Group’s...
NYSE:ACCO
NYSE:ACCOCommercial Services

ACCO Brands (ACCO) Return To Profit Tests Bearish Earnings Narrative

ACCO Brands (ACCO) has reported its FY 2025 third quarter with revenue of US$383.7 million and EPS of US$0.04, alongside net income of US$4 million. The trailing 12 month figures show revenue of US$1.54 billion and EPS of US$0.44 supported by net income of US$40.6 million. Over recent quarters the company has seen revenue move from US$438.3 million with EPS of a US$1.29 loss and a net loss of US$125.2 million in Q2 2024 to US$394.8 million with EPS of US$0.32 and net income of US$29.2 million...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Assessing Nuvalent (NUVL) Valuation After Wider Losses And A New Shelf Registration

Why Nuvalent’s latest results are in focus Nuvalent (NUVL) is back on investors’ radar after reporting a fourth quarter net loss of US$118.71 million and a full-year net loss of US$425.38 million, along with a new US$458.37 million shelf registration filing. See our latest analysis for Nuvalent. At a share price of US$102.32, Nuvalent has seen a 1-day share price return of 2.93% and a year-to-date share price return of 1.47%. Its 1-year total shareholder return of 51.86% and very large 3-year...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Is Starbucks (SBUX) Pricing Look Stretched After Recent Share Price Rebound?

Wondering if Starbucks at around US$99.77 is offering you real value today, or if the easy money has already been made? You are not alone in asking whether the current price lines up with what the business is actually worth. The stock has returned 3.1% over the last 7 days, 0.3% over the last 30 days and 18.8% year to date, with a 1.4% return over 1 year, 8.4% over 3 years and 2.8% over 5 years, which gives investors a mixed set of signals about recent momentum and changing risk...
NasdaqGS:TRMB
NasdaqGS:TRMBSoftware

Trimble’s Paris Grand Role And Insider Selling Shape Valuation Picture

Trimble is supplying technology for the Paris Grand construction project, keeping the company tied to one of Europe’s highest profile infrastructure builds. At the same time, company insiders have been consistently selling shares of NasdaqGS:TRMB over the past year, with no insider purchases reported. These two threads, project execution in France and insider activity at home, give investors fresh information on Trimble beyond recent earnings headlines. Trimble, trading at $70.45, sits at...
NYSE:AMPX
NYSE:AMPXElectrical

Amprius Revenue Record And SiCore Wins Tested Against Rich Valuation

Amprius Technologies (NYSE:AMPX) reported record fourth quarter revenue. The company highlighted broad adoption of its second generation SiCore silicon anode batteries. Nokia Drone Networks selected Amprius SiCore batteries, adding a high profile commercial reference. Amprius said it is ahead of schedule on NDAA compliance, improving eligibility for future U.S. government contracts. Amprius focuses on high performance silicon anode batteries aimed at applications where weight, power, and...
NYSE:PNFP
NYSE:PNFPBanks

Is Pinnacle Financial Partners (PNFP) Pricing Reflect Recent Regional Bank Concerns Accurately?

If you are wondering whether Pinnacle Financial Partners is offering fair value at its current share price, you are not alone. This article is designed to help you frame that question clearly. The stock last closed at US$87.29, with returns of a 5.8% decline over 7 days, a 14.6% decline over 30 days, an 8.2% decline year to date, an 11.1% decline over 1 year, 58.6% over 3 years, and 1.1% over 5 years, which gives a mixed picture of recent and longer term performance. Recent news around...
NYSE:RBLX
NYSE:RBLXEntertainment

Roblox Creator Push And AI Safety Tools Meet Depressed Share Price

Roblox has launched two new creator programs, Roblox Incubator and Roblox Jumpstart, aimed at helping developers build higher quality games for a more mature audience. The company has also rolled out AI-powered chat moderation that can automatically rephrase inappropriate messages in real time to help keep conversations safer and more civil. Roblox, listed as NYSE:RBLX, is introducing these creator programs and AI tools at a time when its share price is $62.65. The stock has seen a 16.5%...
NYSE:HRTG
NYSE:HRTGInsurance

Heritage Insurance (HRTG) Combined Ratio Breakthrough Reinforces Bullish Profitability Narrative

Heritage Insurance Holdings (HRTG) just posted its FY 2025 third quarter results, reporting revenue of US$212.5 million and basic EPS of US$1.63, alongside a combined ratio of 72.9%. This puts underwriting performance in clear focus. The company’s quarterly revenue has moved in a tight band, from US$210.3 million in Q4 2024 to US$212.5 million in Q3 2025, while basic EPS increased from US$0.66 to US$1.63 over the same period. This sets the scene for investors to examine how margins and...
NasdaqGM:FCEL
NasdaqGM:FCELElectrical

FuelCell Energy (FCEL) Q4 Revenue Reaches US$55 Million Yet Losses Challenge Bullish Narratives

FuelCell Energy (FCEL) has opened Q1 2026 earnings season with Q4 2025 numbers that show total revenue of US$55.0 million and a basic EPS loss of US$0.85, alongside net income excluding extra items of a US$30.7 million loss. Over the past few quarters, the company has seen revenue move from US$23.7 million in Q3 2024 to US$49.3 million in Q4 2024 and then to US$55.0 million in Q4 2025. Quarterly basic EPS stayed in loss territory, ranging from a US$2.21 loss per share in Q4 2024 to a US$3.78...
NasdaqGS:SWBI
NasdaqGS:SWBILeisure

Does Smith & Wesson (SWBI) Earnings-Driven Dividend Stability Mask Deeper Profitability Pressures?

In early March 2026, Smith & Wesson Brands, Inc. reported that its third-quarter sales rose to US$135.71 million and net income to US$3.75 million, while affirming a quarterly dividend of US$0.13 per share payable on April 2, 2026. An interesting contrast is that, despite higher quarterly sales and earnings year on year, net income for the first nine months fell to US$2.26 million from US$4.79 million, highlighting pressure on profitability over the longer period. We’ll explore how the...